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THE TROPHIC EFFECTS OF ESTRADIOL ON VIRALLY TRANSFORMED 
HYPOTHALAMIC CELL LINES 
Jane Elliott Rasmussen 
1990 
Although it appears that the perinatal development of 
sexual phenotype in the rodent brain is determined by 
exposure to estradiol, generated locally via aromatization 
of androgen, the mechanisms underlying this process are 
not fully understood. The development of an in vitro model 
of hormone action based upon examining the effects of sex 
steroids on estrogen-sensitive fetal rat hypothalamic cells 
could provide important information. Therefore, using 
serum-free, growth factor-deficient conditions the effects 
of 17 alpha- and 17 beta-estradiol, testosterone, 5 alpha- 
dihydrotestosterone (DHT), and tamoxifen on survival of two 
SV-40 transformed estrogen-receptor positive rat 
hypothalamic cell lines were examined, with the hope of 
establishing an in-vitro model of sexual differentiation of 
the rat hypothalamus. In one cell line, designated RCF-8, 
both 17 beta-estradiol and testosterone significantly 
increased cell survival at picomolar concentrations. The 

effects of both estradiol and testosterone were blocked by 
tamoxifen, and they could not be reproduced by the non- 
aromatizable androgen, 5 alpha-dihydrotestosterone or the 
inactive estradiol isomer, 17 alpha-estradiol. In the other 
cell line, RCA-6, addition of 17 beta-estradiol led to 
inhibition of cellular proliferation, which was reversed by 
the addition of tamoxifen. In an estrogen receptor-negative 
hypothalamic cell line, RCF-12, estradiol had no net effect 
on the growth pattern. 
After establishing the properties of this model cell 
line, RCF-8, the effects of estradiol treatment on the 
response to endogenous hypothalamic growth factors was 
examined. For these studies we chose insulin and insulin¬ 
like growth factor I (IGF-I). We found that estradiol 
induces competence such that RCF-8 cells have a mitogenic 
respond to IGF-I, but not to insulin. 
In summary, the estrogen binding capacity and the 
responsiveness to physiologic concentrations of estradiol 
and testosterone, but not DHT, make the RCF-8 cell line a 
potential in vitro model of hypothalamic sexual 
differentiation and through the use of this estrogen- 
sensitive hypothalamic cell line model, we have a unique 
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INTRODUCTION 
Sexual dimorphism is obvious in most mammalian species 
because of the differential development of internal and 
external genitalia as well as extragenital features such as 
body size. The term "sexual dimorphism" refers to any 
differences in form regardless of whether they are manifest 
at the behavioral, morphologic or molecular level. In the 
central nervous system, sexual differentiation is present 
in many vertebrate species, including hamster, mouse, rat, 
various bird species, as well as human beings (1-5). 
Divergence occurs both structurally, in the size of 
specific brain nuclei, neuronal morphology and in synaptic 
networks (i.e. patterns of neuronal connectivity and 
dendritic branching patterns), as well as functionally in 
sex specific behavioral patterns, regulation of food intake 
and body weight, and reproductive physiology (6-11). There 
are three well-characterized areas in the central nervous 
system, that show marked anatomical differences between the 
sexes: the sexually dimorphic nucleus of the pre-optic area 
in the rat, the song nuclei in the zebra finch and the 
canary, and the spinal nucleus of the bulbocavernosus in 
the rat spinal cord. In each of these systems nuclear 
volume and cell number are higher in the male. 
The concept of sexual dimorphism of the brain implies 
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that the many functional and structural differences evident 
in mammalian brain are not due to autonomous sex 
differences but rather are imposed on an inherently female 
or at a minimum bipotential brain during development. The 
aspects of brain function characteristic of the male are 
manifest in the developing brain through the action of 
hormones at a critical period in development (12). For 
example, human embryos of both sexes develop in an 
identical fashion for the first two months of gestation, 
and only thereafter do anatomical and physiological 
development diverge to result in the formation of the male 
and female phenotypes. The period of greatest sensitivity 
to gonadal hormones in terms of sexual differentiation 
varies with the developmental state of the organism at 
birth (i.e., in some species hormones act prenatally; in 
others perinatally and in some, hypothetically, could act 
postnatally). It should be mentioned that separate 
functional systems in the central nervous system may 
differentiate independently both in terms of the period of 
development and in qualitative and quantitative hormonal 
sensitivity, i.e. the critical period of development of one 
hypothalamic nuclei or analogous system, may occur prior to 
differentiation of another and that the concentration of 
hormone needed to elicit the change in one system may 
differ from another. 
The basic experimental approach that has been used to 
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document the concept of sex-steroid brain sexual 
differentiation has been to modify the hormonal environment 
perinatally. This is generally accomplished by exposing 
embryonic/fetal females to exogenous androgenic steroids or 
by preventing exposure of the perinatal male to endogenous 
testicular hormones by gonadectomy or drug treatments. 
Subsequently, physiological, behavioral or anatomical 
differences are then sought in adulthood. 
The initial reports of sex-specific brain differences 
appeared in the late 1920's and early 1930's. The first 
noteworthy experiments concerning sexual differences in the 
brain were performed by Pfeiffer (13) over 50 years ago. In 
an elegant set of experiments, he showed that the 
expression of masculine patterns of pituitary gonadotropin 
secretion in adulthood was dependent on factors released 
from the testes during early postnatal life. Thus, the 
development of masculine patterns of gonadotropin secretion 
could be induced in genetic females by transplantation of a 
testis shortly after birth; whereas castration of genetic 
males at birth resulted in the development of the 
characteristically female patterns of gonadotropin release. 
Alfred Jost between 1947 and 1952 is credited with the 
elucidation of the fundamental mechanism of sexual 
dimorphism. The Jost formulation states that sexual 
differentiation is a sequential, ordered and relatively 
simple process. Chromosomal sex directs the development of 
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either ovaries or testes. If testes develop, the hormonal 
secretions elicit the development of the male phenotype. If 
the ovaries develop or if no gonad is present, anatomical 
development is female. Thus, whatever the mechanisms by 
which chromosomal or genetic sex is translated into gonadal 
sex, it is the action of the gonads as endocrine organs 
that is responsible for the development of the sexual 
phenotypes. 
One of the most divergent brain systems is the sexually 
dimorphic nucleus of the preoptic area (SDN-POA) of the rat 
hypothalamus in which anatomical differences are so marked 
that one can sex the brain with the unaided eye after 
thionin-staining. Within the last fifteen years using the 
rat hypothalamus as their model, Gorski and co-workers (14- 
16) have carefully shown that treatment of female rats with 
testosterone propionate injections from day 16 gestation 
through the first ten days of postnatal life produces an 
irreversible and permanent masculinization of the brain as 
documented by lordosis reflexes, receptivity and mounting 
behavior, as well as the striking anatomical differences in 
the preoptic area. In male rats the volume of the SDN-POA 
is 5-7 times greater than that of the female. Since 
neuronal volume is not increased, this means that the 
number of neurons comprising the nucleus in the male is 
significantly greater than in the female. In addition, 
Jacobson et. al. (17), again using the SDN-POA, were able 

5 
to show that gonadectomy of male fetuses neonatally has 
equally permanent effects, leading to genetic males with 
"female" brains, (i.e. male fetuses which underwent 
castration showed no specific increase in volume of the 
SDN-POA). 
As it was established that differences in the hormonal 
environment could lead to anatomical changes in the rat 
brain, the next problem was to determine which hormone or 
hormones were influencing the cells in these areas. A 
number of possibilities needed consideration. Since 
testosterone treatment can essentially substitute for the 
testes in inducing masculine patterns of gonadotropin 
release and behavior (18), it seemed likely that either 
testosterone, aromatized metabolites of testosterone such 
as estradiol, or reduced metabolites of testosterone such 
as 5 alpha-dihydrotestosterone were the responsible 
agent(s). In 1972, Davidson and Levine (19) suggested that 
the "future masculinization of the reproductive behavioral 
pattern is the result of the action of androgen at a 
critical period in early development. In the absence of 
circulating androgen, the brain remains in its neutral 
state which is one of potential femaleness". This 
hypothesis assumes that under normal physiological 
circumstances, during the critical period of development 
there must be a high concentration of androgen in the 
circulation of the male, but an absence of androgen in the 
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female animal. It is premature, however, to conclude that 
sexual dimorphic phenomenon in the brain are simply a 
function of the presence in male and absence in females of 
unbound circulating testosterone. Radioimmunoassay 
measurements have shown that in the rat, androgens 
circulate in females as well as in males during the 
critical period when sexual differentiation of the central 
nervous system occurs. The actual amounts of androgen 
necessary for brain dimorphism still remains controversial. 
Some reports have demonstrated consistently higher 
testosterone concentrations in males than in females during 
early post-natal life (20), whereas others have shown a 
considerable overlap in the amounts present in the two 
sexes (21). 
During the 1940's several workers reported the 
surprising fact that treatment of female rats with high 
doses of estrogen prior to or shortly after birth resulted 
in a pattern of anovulatory sterility in adulthood which 
closely resembled that observed after perinatal 
testosterone administration (22-24). Subsequent work 
confirmed and extended this finding; many of the effects of 
testosterone on the developing brain could be reproduced by 
estrogen (25). 
In the early 1970's it was well known that androgens, 
which were made by the gonad or adrenal gland could be 
converted by an aromatase enzyme elsewhere (peripheral 
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conversion), furnishing a considerable portion of the daily 
production of estrogens (26). It therefore seemed likely 
that similar metabolic transformations could occur in the 
central nervous system. The aromatase hypothesis (27), 
proposing that estrogens formed in or near their target 
cells from androgen precursors could account for the action 
of testosterone in certain neuroendocrine processes such as 
brain differentiation, was developed conceptually to 
account for the above findings. The central tenet of this 
hypothesis is that estrogen is produced locally via 
aromatization and acts as a regulatory agent. This 
hypothesis was satisfying for several reasons: local 
production of the hormone 1) avoids unnecessary exposure of 
the entire body to active hormone metabolites on their way 
from a distant producing cell; 2) it avoids the need for 
large amounts of product to overcome dilution in the blood 
stream; and 3) it provides a localized feedback loop for 
efficient control of the estrogen effects. The full impact 
of the above work and subsequent aromatase hypothesis did 
not become apparent until the early to mid 1970's when 
three observations firmly established the role of estradiol 
in the process of sexual dimorphism. First, 5 alpha- 
dihydrotestosterone (DHT) and other ring A reduced 
androgens were shown to be far less effective than either 
testosterone or estradiol at inducing defeminization of the 
neonatal rat brain (28-30). Secondly, the effects of 
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testosterone treatment in neonatal female rats could be 
blocked by estrogen antagonists (31). Finally, the 
developing brain, like many peripheral tissues was found to 
be a site of androgen to estrogen conversion (32). The 
above findings clearly establish that exposure of the 
developing brain to estrogen effects mammalian sexual 
development in much the same way as early exposure to 
testosterone. 
In placental mammals, the fetus is continually exposed 
to endogenous estrogen from the placenta and maternal 
circulation. If estrogen formation within the brain plays a 
vital role in sexual differentiation, then it follows that 
the fetal brain must somehow be protected from the 
influence of high effective circulating estrogen levels. In 
rats and mice the mechanisms of this protection are well 
established. In each of these species, the immature brain 
is functionally denied circulating estrogen by a plasma 
estrogen binding system. The developing yolk sac and fetal 
liver synthesize an estrogen binding protein (fetoneonatal 
estrogen binding protein, or FEBP) which circulates at high 
concentrations during the latter part of gestation and then 
gradually disappears over the first few weeks of postnatal 
life (33-34). This protein, which is immunochemically 
indistinguishable from the plasma alpha-globulin, alpha- 
fetoprotein, binds and effectively sequesters virtually all 
of the estrogen present in the fetal and neonatal 
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circulations (8,35). Significantly, it binds testosterone 
poorly: hence testosterone is free to enter the brain where 
it can be converted locally to estradiol via aromatization. 
Several experimental observations have confirmed the 
effectiveness of the FEBP protection mechanism. Although 
the levels of estradiol in the blood of the neonatal rat, 
both male and female, are high, free estradiol does not 
seem to be readily available in the tissues (36-37). The 
administration of antibodies to alpha-fetoprotein in 
newborn rats produces effects on sexual development that 
resemble those of estradiol or testosterone injections 
(38). 
It is not possible to extend the FEBP binding 
hypothesis species other than rats and mice as of yet. 
Although alpha-fetoprotein is present in many vertebrate 
species, the ability to bind estrogen seems to be property 
of the particular species-specific alpha-fetoprotein. As we 
are able to detect similar sexual dimorphic phenomenon in 
species other than rat, including man, there must exist an 
as of yet undetermined alternative protection system. There 
is evidence, however, suggesting that the aromatase 
hypothesis may be important in species other than rat, such 
as guinea pigs and humans (27). 
Once estrogen is formed locally in the brain how does 
it modulate the final number of neurons in the SDN-POA? 
Gorski, as well as other investigators (8,35,39) have 
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postulated several mechanisms, not necessarily mutually 
exclusive, including: 1) estrogens may stimulate or prolong 
neurogenesis; 2) estrogens may influence the migration of 
neurons from their origin in the ependymal lining of the 
third ventricle to the region of the SDN-POA; 3) in the 
vicinity of the SDN-POA estrogen may promote the 
aggregation of these neurons into the distinct nucleus, 
perhaps by altering a cell surface recognition factor; 4) 
estradiol may promote neuronal survival during the phase of 
programmed neuronal death; and 5) estradiol may influence 
the specification of neurons destined to form the SDN-POA, 
that is, by activating or suppressing certain genes, 
estradiol determines the functional specificity and thus 
perhaps the migration, aggregation and even survival of 
more neurons in the male. 
Although, the exact cellular mechanism(s) by which 
estrogen ultimately increases the final number of SDN-POA 
neurons remain to be elucidated, estrogenic regulation of 
other cell types in vivo, and in vitro provides important 
insights into the way the process may occur in the central 
nervous system (40-45). Direct interactions with estrogen 
receptor positive target cells and indirect interactions 
via production or modulation of local growth factors to 
increase cellular proliferation have been reported (46-48). 
It seems reasonable to suppose that similar mechanisms may 
underlie the developmental effects of estrogens on the 
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central nervous system. The most widely accepted hypothesis 
(43,44,49-52) for estradiol's action advocates a direct 
estrogenic effect. In this view, estradiol binds to a 
specific nuclear or cytoplasmic receptor in the 
representative cell (including neuronal cell types), 
followed by translocation of the complex to the cell 
nucleus and initiation of the cellular response(s) (9). The 
newer appreciation of the role of local growth factors in 
brain formation raises the question about indirect estrogen 
effects mediated by such growth factors. 
During the development of the mammalian brain many 
neurons are formed which never survive to adulthood. The 
inability of many neurons to obtain sufficient support from 
local neurotropic factors leads to their death. This 
overproduction of neural precursor cells and competition 
for limited neurotrophic support, termed "programmed cell 
death", occurs in both the central nervous system as well 
as in the peripheral nervous system (53-54). 
Experimental models of neurotrophic influences need to 
attempt to recreate this pattern of selective survival, 
furnishing systems with limited support and declining cell 
number. The prototypical neurotrophic factor is nerve 
growth factor (NGF). Many investigators have documented 
NGF's neurotrophic effects using model systems (55-58). 
For many years, NGF was believed to be the only 
neurotrophic factor. Recent work from numerous 
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investigators (58) has shown that many other ubiquitous 
growth factors need to be considered as neurotrophic 
factors. The experimental element limiting the 
identification of other neurotrophic factors is that 
defined neuronal culture systems are difficult to 
establish. These systems are necessary so that the activity 
of putative trophic agents can be quantified from data on 
the ability to support neuronal survival. 
The somatomedins or insulin-like growth factors, 
constitute a family of peptide growth factors which are 
structurally and evolutionarily related, possess insulin¬ 
like activity, and have mitogenic effects in a wide variety 
of cell types. Two major human somatomedins have been 
purified and sequenced. Insulin-like growth factor I (IGF- 
I) and insulin-like growth factor II (IGF-II). Insulin¬ 
like growth factor I is a basic peptide of 70 amino acids 
with a molecular weight of 7649. Structurally, the adult 
form is a single polypeptide chain with 3 disulfide 
bridges, having strong structural homology with human 
proinsulin. It is synthesized and secreted de novo in many 
tissues, including liver, kidney, testes, submaxillary 
gland, pancreas, heart and nervous system. The highest 
levels are found in the liver and the brain. In addition, 
there is a fetal form which varies somewhat in structure 




There has been considerable controversy concerning 
the presence of IGF-I in the brain (59-60). Much of the 
confusion resulted because it was not recognized initially 
that a fetal brain form of IGF-I existed and researchers 
were unable to detect IGF-I immunoreactivity in the adult 
brain (61). The existence of a fetal form was proposed by 
Sara et. al. (62) based on the presence of fetal tissue 
somatomedin receptors, and somatomedin growth-promoting 
activity on fetal cells in vitro (63-64) despite low or 
undetectable levels of immunoreactive adult IGF-I or IGF-II 
in fetal serum. The presence of the fetal form of IGF-I was 
proven by utilizing a radioligand receptor assay utilizing 
human fetal brain plasma membrane receptor as the matrix 
and IGF-I as the ligand (62). This method revealed elevated 
levels of somatomedins (not attributed to either 
immunoreactive IGF-I or IGF-II) in the fetal circulation in 
levels four times that seen in adult. The fetal form of 
IGF-I is thought to be unique to the central nervous system 
found only in the fetal and early neonatal animal. The 
levels in brain tissue slowly decline after birth to 
nondetectable levels in the adult. A transition from 
production of fetal to adult forms of somatomedins at about 
the time of birth has also been proposed (62). It is 
noteworthy that in healthy newborns, a significant 
correlation was found between fetal brain serum somatomedin 
levels and birth weight and length (62). This finding 
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suggests that embryonic/fetal IGF-I may play an active role 
in the regulation of fetal brain development and growth and 
perhaps in early postnatal brain growth. We postulate that 
estrogens may act to increase the survival of certain 
neurons by interacting with local factors such as IGF-I. 
A problem in testing this hypothesis, however, is that 
the substrate on which steroids act in the developing brain 
consists of a heterogeneous population of cells, only a 
small proportion of which contain estrogen receptors. In 
the normal brain, responses to estrogen action occur 
against a background of developmental events in estrogen- 
insensitive neuronal and glial systems that may mask the 
specific effects of the hormone. Even where a response to 
estrogen is observed, it may be difficult to determine 
whether it is due to direct or indirect actions of the 
hormone, since effects on the primary steroid target cell 
may be transmitted to many other cells through changes in 
the release of neurotransmitters or neuromodulators by 
other cells or by the target cell itself. 
Because of the complexity of intracellular signalling 
in the developing central nervous system, we have attempted 
to examine the effects of estrogen on the survival of a 
single isolated neuronal precursor cell. Dr. Robbins' 
laboratory has transformed millions of fetal hypothalamic 
precursor cells by infection with simian virus 40 (SV-40). 
The resultant cell lines were screened for the presence of 
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numerous specific neuronal antigens, glial antigens and 
estrogen receptors. 
By the use of such immortalized cell lines, we were 
able to examine the action of a specific hormone (e.g. 
estradiol) on a single cell type. We were interested in: 
1) identifying a hypothalamic cell line that could 
specifically bind estradiol (i.e. possesses estrogen 
receptors). 2) show increased cell growth or survival of 
an estrogen-receptor positive cell line as a direct result 
of estradiol action, 3) demonstrate aromatase activity by 
inducing a growth response of the cells when exposed to 
testosterone, and 5) induce no growth increase upon 
exposure of the cell line to 5 alpha-dihydrotestosterone. 
Upon identifying such a cell line, we were interested 
in exploring the possible mechanism(s) of action for 
estrogen in sexual dimorphism. Specifically, we were 
interested in exploring whether the estradiol effect of 
increasing cell number could be due to modulation of the 
action of another local hormone or tissue growth factor. 
Because of evidence suggesting the presence of a unique 
fetal brain form of insulin-like growth factor I activity 
this is where we focused our attention. Using our model 
cell line, we examined the effects of treatment with 1) 
estradiol and IGF-I alone and in combination; and 2) 
estradiol and insulin alone and in combination. 
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MATERIALS AND METHODS 
Materials 
SV-40 virus (B381,2x10spfu/ml) was a gift from Dr. J. 
Cook (National Asthma Center, Denver CO.). All steroids and 
other chemicals, unless otherwise stated, were purchased 
from Sigma (St. Louis, MO.). There was no further 
purification of these substances before use. 3H- 17 beta- 
estradiol (114.4 Ci/mmol) was purchased from New England 
Nuclear. Estrogen-deficient gelded horse serum was 
purchased from the Lowell Crowther Ranch (P.0. Box #8 
Sanford CO. 81151). Recombinant insulin-like growth factor 
I was purchased from Bachem (Torrance, CA.). Purified 
Porcine insulin was obtained from Sigma (St. Louis, MO.). 
Preparation of the transformed cell lines 
The cell lines coded RCF-8, RCF-12 and RCA-6 were 
obtained from rat fetal hypothalamus (embryonic day 16) 
irrespective of genetic sex, and were virally transformed 
using SV-40 virus according to methodology reported 
previously (65). Briefly: Rat embryos were removed by 
Cesarean section from timed pregnant Sprague-Dawley rats 
and their brains dissected. The basal diencephalon from 
each embryo was isolated and pooled together. The pooled 
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diencephalon were dispersed by gentle trituration in a 
0.01% papain- 0.1% neutral protease- 0.01% 
deoxyribonuclease solution. The resultant cell suspension 
was washed and resuspended in Earle's minimal essential 
medium (MEM,Gibco) containing 10% fetal calf serum (FCS). 
The cells were counted using a hemocytometer. Cells (4xl06) 
were incubated for 3 hours at 37°C with 5xl07 pfu of SV-40 
virus, a final concentration of 12.5 pfu/cell. After virus 
absorption, the cells were plated in 25 cm2 flasks, and 
observed for development of transformed foci. Plating 
medium was Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 5mM glucose and 10% FCS. Foci of rapidly 
dividing cells were collected by trypsinization and diluted 
to a concentration of 0.1 cell/ml and then plated in 
microtiter plates in the same medium. This process of limit 
dilution was used to ensure that each cell line originated 
from a single cell. Wells which contained confluent cell 
layers were then trypsinized, rediluted, as before, and 
then replated. All of the cell lines were found to express 
the SV-40 large T antigen, determined by the immuno- 
fluorescent method of Pope et. al. (66). In addition, these 
cell lines were found to express both neural and glial 
markers. 
We have noted that RCF-8 cells older than 25 passages 
occasionally develop an increased basal growth rate 
simultaneous with a loss of estrogen responsiveness. The 
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normal phenotype is recovered by thawing cells stored in 
liquid nitrogen from very early passages. In one case we 
sub-cloned the RCF-8 cells by limit dilution and were able 
to recover many cell lines which retained the estrogen 
responsiveness of the parental line. 
Cell culture 
Stock cultures of the cell lines were routinely grown 
in 75 cm2 flasks containing MEM supplemented with 10% FCS, 
2 units/ml penicillin (Gibco), 2 units/ml streptomycin 
(Gibco) and 33mM dextrose. The cells were grown at 37°C in 
5% carbon dioxide-95% humidified air as monolayer cultures 
and were subcultured at weekly intervals. 
Cells from subconfluent stock flasks were suspended by 
treatment in 0.25% trypsin/2mM EDTA at pH 7.6, washed, 
resuspended in serum-free media, counted, and then plated 
in multiwell polystyrene dishes (35mm) at an initial 
density of 105cells/well. Passages between 10 and 27 for 
RCF-8, between 10 and 69 for RCF-12 and between 10 and 73 
for RCA-6 were used for experiments. Cells were cultured in 
2 ml. of DMEM-Ham's F-12 (1:1) without phenol red, 
supplemented with 1.2gm/liter NaHC03 , 15mM HEPES, O.lmg/ml 
transferrin, 10'5M putrescine, 2x10" 8M progesterone, 10' 7M 
corticosterone, 10“ 5M triiodothyronine, lug/ml arachidonic 
acid, and 2x10'8M Na2Se03 (67). The pH indicator phenol red 
was eliminated from the experimental media because of its 
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reported estrogenic properties (68). The steroids were 
added from stock solutions in ethanol so that final 
concentrations of ethanol were less than 0.01%. Test 
peptides were diluted in culture medium from a stock 
solution just before use. Cultures were maintained for 7 
days. At the end of this time, adherent cells were 
resuspended by trypsinization and counted using a 
hemocytometer. Unless otherwise indicated, in every 
experiment all treatments were done in triplicate. 
Throughout the week in culture the number of viable 
cells (x 104) present after plating 105 RCF-8 cells at 
several time points was: day 2, control 1.65 + 0. 23, 
estradiol (1 pM) 3.25 ± 0.50; day 4, control 1.28 _+ 0.15, 
estradiol 2.53 _+ 0.23; day 6, control 0.86 _+ 0.11, 
estradiol 2.11 _+ 0.17 (triplicate experiments, total n=12 
for each point). 
Binding studies 
Cell lines obtained by the method outlined above were 
screened for the ability to bind 17 beta-estradiol using a 
modification of a well characterized 3H-estrogen nuclear 
binding assay (69). Briefly: 24 hours prior to each study, 
cells from stock cultures, confluent T75 flasks, were 
transferred to medium containing gelded horse serum. At 
t=0, 3H-estradiol was added to each flask to a final 
concentration of 2x10“ 9M. Control flasks for non-specific 
binding received the isotope and excess (1x10' 7M) 
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diethylstilbestrol (DES). The flasks were incubated at 37°C 
for 1 hr. and then put on ice. The medium was removed and 
the cell layer scraped off using a rubber policeman. The 
cells were homogenized in a buffer containing 0.32 M 
sucrose, 3mM MgCl2 , lmM potassium phosphate, 0.025% Triton- 
X 100, pH 6.5 and the nuclei isolated by centrifugation at 
850g for 10 minutes. The nuclear pellet was washed twice in 
the above buffer without Triton-X 100 and then extracted 
overnight by incubation with ethanol. The ethanol extracts 
were counted in Opti-fluor and the DNA in the extracted 
pellets was assayed by the method of Burton (70). Results 
of the binding studies were expressed as amount (fmol) of 
specific nuclear binding per mg of DNA. Specific binding 
was calculated as the difference between the results in the 
presence and absence of DES. All binding studies were done 




Estrogen Binding Studies 
Four of fifteen screened rat hypothalamic cell lines 
(RCF-8, RCA-6, RCF-17 and RCD-15) displayed measurable 
estradiol binding (>5 fmol/mg DNA). The highest specific 
binding (132.1 fmol/mg DNA) occurred in the RCF-8 cell 
line. The next highest level (23.1 fmol/mg DNA) was present 
in the RCA-6 cell line. The other two lines that displayed 
measurable binding, RCF-17 and RCD-15, had values of 21.5 
fmol/mg DNA and 7.82 fmol/mg DNA, respectively. Eleven cell 
lines, including RCF-12, exhibited no specific binding in 
this assay. 
Effects Of Estrogen On Cell Growth 
RCF-8 cells were growth arrested by plating at a low 
density in a serum-free medium (see methods). By day 7 in 
vitro, 105 RCF-8 cells had declined to 0.63 _+ 0.21 x 104 
viable cells per well ( mean ± SD, n=78). The effects of 17 
beta-estradiol and 17 alpha-estradiol on the survival of 
these cells, under these conditions are depicted in Figure 
1A. 17 beta-estradiol, at every concentration tested 
between 1 pM and 1 uM significantly (p< 0.025) increased 
the number of viable cells present on day seven. The 
maximal response was observed with 1 pM 17 beta-estradiol, 
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which resulted in a more than three-fold increase in 
surviving cells (1.91 _+ 0.29 x 104 viable cells; n=30, p< 
0.01). Higher concentrations of 17 beta-estradiol (up to 1 
uM) also significantly increased cell survival, but the 
magnitude of the effect progressively declined as the 
concentration increased. Neither 0.1 nor 10 fM 17 beta- 
estradiol increased the survival of RCF-8 cells in this 
paradigm. 17 alpha-estradiol did not increase cell survival 
at any concentration tested. Estriol (100 pM) also 
significantly (p<0.05) increased the number of surviving 
cells on day seven (control 0.98 +_ 2.14 x 104 ; treated 1.84 
_+ 0.34 x 104 ; mean ± SD, n=9) . The enhanced cell survival 
induced by 1 pM 17 beta-estradiol was completely reversed 
by the addition of 100 pM tamoxifen (Figure IB) although 
tamoxifen alone (100 pM) had no effect on cell survival. 




Figure 1A: Effects of 17 beta-estradiol (-o-) and 17 alpha- 
estradiol (-•-) on the RCF-8 cell line after seven days in 
culture. All values (mean +. S.D., n= 9 to 30) for 
treatments with 17 beta-estradiol were significantly (p< 
0.05) different than the control value. Values for 
treatments with 17 alpha-estradiol (n= 9 to 18) were not 
statistically different than control. 
Figure IB: Blockade of the 17 beta-estradiol effect (lpM) 
with tamoxifen (lOOpM) in RCF-8 cells. Treatment values are 
compared to the number of cells present at 7 days in 







The effects of estradiol on another cell line which 
exhibited estradiol binding, RCA-6, were also examined. In 
contradistinction to RCF-8, this cell line continues to 
proliferate and increase in number when grown in serum-free 
conditions. After 7 days in vitro the initial 105 cells 
increased to 2.19 _+ 0.76 x 106 (mean +. SD, n=33). 17 beta- 
estradiol significantly (p<0.05) decreased the number of 
cells present on day 7 (Figure 2A). The maximal effect 
occurred with a concentration of 100 pM. At this dose, 17 
alpha-estradiol had no effect on cell number. Tamoxifen 
(100 pM) completely blocked the inhibitory effect of 
estradiol, although it had no effect alone (Figure 2B). No 
changes in cellular morphology were evident in the RCA-6 




Figure 2A: Effect of 17 beta-estradiol (-o-) on the RCA-6 
cell line after seven days in culture. Treatment values 
(mean _+ S.D., n = 9 to 33) obtained at lOOpM and 10 nM 17 
beta-estradiol were significantly (p<0.05) different from 
control. 
Figure 2B: Blockade of the 17 beta-estradiol (lOOpM) effect 
with tamoxifen (lOOpM) in the RCA-6 cell line. Treatment 
values are compared to cells grown in the absence of 





The RCF-12 cell line was used as a control because it 
had no detectable estrogen binding. No significant 
differences in cell number compared to untreated cells were 
present after seven days of exposure to 17 beta-estradiol 
(10"12 M, 10"10 M and 10" 8M; data not shown). 
Effects Of Testosterone And Dihydrotestosterone On Cell 
Growth 
The response of the RCF-8 cell line to testosterone, an 
aromatizable androgen, and dihydrotestosterone (DHT), a 
non-aromatizable androgen is shown in figure 3A. 







positive effect on cell number. When used at the 
concentration that produced a maximal effect for 
testosterone, 100 pM, DHT had no significant effect on cell 
number. As with 17 beta-estradiol, the enhancement of 
survival by testosterone declined with concentrations above 
100 pM. Tamoxifen (100 pM) completely blocked the maximal 
testosterone response in the RCF-8 cell line (Figure 3B). 
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Figure 3A: Effect of testosterone (-o-) and 
dihydrotestosterone (-• -) on the RCF-8 cell line after 
seven days in culture. The values obtained (mean _+ S.D., n 
=9 to 15) for treatment with testosterone at lOOpM and 
lOnM were significantly (p<0.05) different than the control 
value. 
Figure 3B: Blockade of the testosterone effect (lOOpM) with 
tamoxifen (lOOpM) in the RCF-8 cell line. Treatment values 
are compared to cells grown in the absence of added hormone 























Interaction between Estradiol and IGF-I on cell growth 
Figure 4 shows that co-addition of IGF-I (O.lnM) and 
estradiol (lpM) results in a synergistic increase in 
proliferation of the RCF-8 cells. While estradiol alone is 
able to stimulate the in vitro survival of RCF-8 cells, 
the RCF-8 cells need the presence of estradiol to be 
stimulated by IGF-I. On the other hand, a dose of InM 
insulin which has been shown to be optimal for stimulating 
cell growth in other hypothalamic cell lines (65), did not 
produce any of the same effects as did IGF-I. Insulin alone 
(lOOnM) or in combination with estradiol (lpM) has no 
effect on cell growth (figure 4). 
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Figure 4: Effect of estradiol, IGF-I and insulin on the 
RCF-8 cell line after seven days in culture. The value 
obtained (mean _+ S.D., n= 9-21) for treatment with 
estradiol (lpM) and IGF-I (O.lnM) was significantly 
(p<0.05) different than the value for treatment with 
estradiol (lpM) alone. The value obtained for treatment 
with estradiol (lpM) and insulin (lOOnM) was not 
significantly different than the value obtained for 
treatment with estradiol (lpM) alone. 
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In other studies, another cell line, RCF-12, was found 
to respond to IGF-I in an estradiol-independent manner. 
IGF-I alone induces a marked proliferative response 




These studies demonstrate the potential of 17 beta- 
estradiol (E2 ) and testosterone (T) to alter the growth 
patterns of cells derived from the fetal rat hypothalamus. 
These clonal cell lines were established to enable us to 
investigate the effects of individual hormones on the 
growth and development of homogenous populations of 
developing hypothalamic cells. The RCF-8 and RCA-6 cell 
lines were chosen for their high E2 binding capacity, when 
compared to thirteen other similar cell lines. 
We employed serum-free conditions in order to create a 
model in which to test for possible neurotrophic effects of 
specific sex steroids. These conditions in which the number 
of hypothalamic cells is progressively decreasing are very 
similar to those used to test potential neurotrophic 
factors in other cell types (55-58) and they mimic, in 
part, the normal programmed cell death which occurs in the 
perinatal rat brain (53-54). 
The survival of RCF-8 cells was increased by E2 . This 
effect was greatest at the physiologic concentration of 1 
pM. The lack of effect of 17 alpha-estradiol and the 
positive effect of higher concentrations of estriol 
strongly support the hypothesis that this effect is 
mediated via specific estrogen receptors. The role of 
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estrogen receptors is further confirmed by the complete 
blockade of the effect with tamoxifen. 
The apparent attenuation of the survival effect in 
response to E2 concentrations above 1 pM remains 
unexplained. Decreasing effectiveness of higher 
concentrations of estradiol on cell growth has been 
reported previously (41). This effect could result from 
desensitization of the estrogen receptors, or from the 
estrogen-induced expression of other genes which might 
limit the survival effects. It is also possible that 
estrogen could be inducing differentiation of the cells, 
which is often associated with decreased proliferation. 
Estrogens have been documented to increase the expression 
of the cellular proto-oncogenes, c-fos and c-myc (71) and 
to induce the production of autocrine and paracrine growth 
factors (72-73) which could promote differentiation. 
The androgens, T and DHT were examined to further 
explore the possibility that RCF-8 cells might serve as a 
model of the cellular events involved in generation of 
sexual dimorphisms in the hypothalamus. Numerous studies 
have demonstrated that sexual differentiation of the rodent 
hypothalamus is dependent on the presence of either 
estrogens or aromatizable androgens, and can be blocked by 
antiestrogens (8). A similar specificity was observed in 
the present studies with respect to steroid-induced 
survival of RCF-8 cells. The maximal T effect was seen at 
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concentrations two log orders of magnitude higher than 
those required for E2 . The inability of equimolar 
concentrations of DHT to reproduce the T effect strongly 
suggests that aromatization of T mediates this response. In 
preliminary direct enzymatic studies done in collaboration 
with Dr. Naftolin's laboratory, the RCF-8 cell line has 
been demonstrated to contain aromatase activity (74). 
We conclude that these cells exhibit the critical 
elements involved in sexual differentiation of the 
developing hypothalamus: i.e. they are estradiol-binding 
hypothalamic-derived cells that exhibit a response to E2 or 
T, but not to the non-aromatizable androgen DHT. 
Furthermore, the presence of aromatase indicates that each 
of the biochemical mechanisms required for response to 
aromatizable androgens may coexist within the same cell. 
Previous studies on the occupation of estrogen receptors in 
the brain after exposure to aromatizable androgens have 
suggested a close functional and structural relationship 
between the aromatase enzyme and the estrogen receptor 
system, since low levels of estrogen biosynthesis in the 
brain are sufficient to occupy a substantial proportion of 
the available estrogen receptor binding capacity (75-76). 
However, the question of whether aromatase is present 
within the estrogen target neurons themselves, or in 
closely neighboring cells, has remained unanswered. 
Although SV-40 viral transformation could clearly have 
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altered the properties of the cells with respect to their 
content of steroid receptors and steroid metabolizing 
enzymes, it seems possible that the normal hypothalamic 
cell from which the RCF-8 line was derived may have 
represented an estrogen-responsive, aromatase-containing 
neuron. 
In contrast to the results with the RCF-8 cells, 
estradiol decreased the proliferation of RCA-6 cells. 
Compared to RCF-8, thi s cell line has a much shorter 
doubling time in serum, has one tenth the estradiol binding 
capacity, and proliferates in the absence of serum. The 
ability of E2 to decrease the rate of proliferation of 
these cells also appeared to be estrogen receptor mediated 
as demonstrated by the effects of 17 alpha-estradiol and 
tamoxifen. Estrogens have been documented to decrease the 
growth rate of other cell types via specific estrogen 
receptor mediated events (see 46 for review). In addition, 
Soto and Sonnenschein (46) have suggested that estrogens 
may induce cell multiplication inhibitors. Although this 
inhibition of proliferation could indicate that E2 is 
inducing differentiation, no phenotypic change in RCA-6 
cellular morphology was noted after exposure to estradiol. 
These studies demonstrate the ability of estradiol to 
modulate the growth patterns of transformed hypothalamic 
cell lines via specific estrogen receptors. These effects 
were present at physiologic concentrations and could be 
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reproduced by the aromatizable androgen testosterone, but 
not by the non-aromatizable androgen DHT. In the RCF-8 
cells deprived of serum, a system in which cell number is 
progressively decreasing, E2 exhibited neurotrophic 
activity. In the RCA-6 cells which proliferate even in the 
absence of serum, Ez decreased the growth rate. 
In addition to establishing cell lines which can be 
used to study sexual dimorphism, we were interested in 
using the model cell line to examine the possibility that 
estradiol exerts it's effects by modulation of response to 
other local growth factors. For this purpose we selected 
IGF-I and insulin which are known to be present at high 
concentrations in fetal brain. Our results indicated that 
estradiol can modulate the growth-promoting effects of IGF- 
I on a hypothalamic cell line which express nuclear 
estrogen receptors. The cell line without estrogen 
receptors (RCF-12) neither responded to estradiol nor 
altered its response to IGF-I by co-exposure to estradiol. 
RCF-8 cells are not responsive to IGF-I in the absence 
of estradiol. One possible explanation is that estradiol 
induces the appearance of type I IGF-I receptors in RCF-8 
cells. However, we have been unable to detect any 
differences in the amount or affinity of IGF-I binding 
sites in RCF-8 cells grown either with or without estradiol 
(77). Thus, estradiol may be necessary to activate an as of 
yet undetermined intracellular mitogenic pathway normally 
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triggered by activated IGF-I receptors. In accordance with 
this possibility estradiol has recently been proposed to 
modulate the coupling of striatal and pituitary dopamine 
receptors to the adenylate cyclase system normally involved 
in postreceptor activation mechanisms (78). In addition, 
estradiol treatment has no effect on the growth of the 
cells treated with insulin. We utilized insulin in these 
studies as a control to monitor the specificity of the IGF- 
I/estradiol synergy. Insulin is a peptide growth factor 
which is structurally closely related to IGF-I suggesting 
that a similar synergy between insulin and estradiol could 
be expected. It is present in high levels in both the 
developing brain and the adult brain (79). The 
concentration of insulin employed, lOOnM, is a 
concentration known to saturate the insulin receptor in 
other hypothalamic cell systems (80). The selectivity of 
the estradiol effect on IGF-I responsiveness but not on 
insulin responsiveness suggests that the IGF-I/estradiol 
interaction may play a unique and significant role in the 
development of the fetal brain, although the exact effects 
and mechanisms remain to be determined. 
Other authors have suggested that a possible mechanism 
whereby ubiquitous growth factors (such as the IGFs or 
fibroblast growth factors) may specifically affect 
particular subsets of cell populations during brain 
development is by interactions between these growth factors 
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and other molecules present in the cellular environment, 
each working at a different phase of the cell cycle (81- 
83). Our data suggests that one such mechanism might be 
explained by the ability of estradiol to allow some 
estrogen sensitive cells to respond to IGF-I. 
We conclude that sex steroids have considerable 
potential to directly and indirectly alter the survival or 
growth characteristics of developing hypothalamic cell 
lines and that these cell lines give us a unique chance to 
study the developmental process of sexual dimorphism using 
an in vitro system. In addition, this work suggests that 
the presence of estrogen at particular stages during 
neurogenesis may constitute a regulatory mechanism whereby 
some estrogen-sensitive cells will start to respond to 
mitogenic/survival signals, such as IGF-I, already present 
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